SALT
LAKE CITY, Sept. 21, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"),
a molecular diagnostics company with a unique, patented platform
for the development of molecular diagnostic tests, announced today
that Co-Diagnostics will be presenting at the Gilmartin Group
Annual Emerging Growth Showcase.
Dwight Egan, Company CEO, will be
participating in a fireside chat discussing Company progress on its
forthcoming Co-Dx PCR Home™ platform on Thursday, September 21 at 11:00 AM ET. The discussion can be accessed
virtually through the Events and Webcasts section of the
Co-Diagnostics website.
The Co-Dx PCR Home platform is subject to FDA review and is
not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-gilmartin-group-annual-emerging-growth-showcase-on-sept-21-301934872.html
SOURCE Co-Diagnostics